Raina N; Shiekh PA; Kumar A; Singh MS; Gupta PK; Gupta M (2023). Oxygen-generating nanomaterials for chronic wound management. Nanomedicine. 18 (11)
Modi SK, Gaur S, Sengupta M, Singh MS*. (2023) Mechanistic insights into Nanoparticle Surface-Bacterial Membrane Interactions in overcoming Antibiotic Re
Swetha KL; Maravajjala KS; Li SD; Singh MS*; Roy A. (2022) Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation. Drug Delivery and Translational Research. 13, 105-134.
Rastogi A; Yadav K; Mishra A; Singh MS; Chaudhary S; Manohar R; Parmar AS. (2022). Early diagnosis of lung cancer using magnetic nanoparticles-integrated systems. Nanotechnology Reviews. 2022-0032.
Singh MS; Ramishetti S; Landesman-Milo D; Goldsmith M; Chatterjee S; Palakuri R; Peer D. (2021). Therapeutic Gene Silencing using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. Small. 17(19);e2100287.
Thakur K; Singh MS; Feldstein-Davydova S; Hannes V; Hershkovitz D; Tsuriel T. (2021). Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer. Genes. 12(8); 1171.
Singh MS; Goldsmith M; Thakur K; Chatterjee S; Landesman-Milo D; Levy T; Kunz-Schughart LA; Barenholz Y; Peer D. (2020). An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. Nanoscale. 12;1894-1903.
Singh MS; Tammam S; Boushehri MAS; Lamprecht A. (2017). MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers. Pharm. Res. 126; 2-30.
Singh MS; Lamprecht A (2016). P-glycoprotein inhibition of drug resistant cell lines by nanoparticles. Drug Dev Ind Pharm. 42(2); 325-31.
Singh MS; Peer D (2016). siRNA delivery: Current trends and future perspectives. Ther. Deliv. 7(2); 51-53.
Singh MS; Lamprecht A (2015). Cargoing P-gp inhibitors via nanoparticle sensitize tumor cells against doxorubicin. Int J Pharm. 478, 745-752.
Singh MS; Juvale K; Wiese M; Lamprecht A (2015). Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation. Eur J Pharm Sci. 77:1-8.
Singh MS; Bhaskar S (2014). Nanoparticle immunotherapy in cancer management and research. Immunotargets Ther. 3; 121-134.
Roy A; Singh MS; Upadhyay P; Bhaskar S (2013). Nanoparticle mediated co-delivery of Paclitaxel and a TLR-4 agonist leads to better tumor regression and enhances anti-tumor immune response at the tumor microenvironment. Int J Pharm. 445; 171-80.
Roy A; Singh MS; Upadhyay P; Bhaskar S (2010). Combined chemo-immunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach. Mol. Pharm. 7; 1778-1788.